Cellares Announces Layoffs Amid Restructuring Following Lost Partnership
Cellares, a cell therapy manufacturing company based in South San Francisco, announced plans to lay off 100 employees as part of a restructuring effort following the loss of an unspecified pharmaceutical partnership. The layoffs are set for completion by October 20 and will primarily affect software engineers, quality control staff, design personnel, and manufacturing specialists. Despite having raised $327 million in its Series D funding just two months ago, Cellares is adjusting to a changed business landscape. CEO Fabian Gerlinghaus stated that while one partnership was lost, other key clients like Bristol Myers Squibb remain committed. The company claims it has more than doubled the number of customers since January 2026. Cellares continues to expand its global footprint with new manufacturing facilities in Europe and Japan and recently joined an FDA pilot program aimed at accelerating regulatory approvals for cell therapy production.
Tickers: $BMY
Topics: Biotechnology Cell Therapy Manufacturing Workforce Reduction